In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
about
Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsEpidemiological and Genomic Landscape of Azole Resistance Mechanisms in Aspergillus FungiVoriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-β-Cyclodextrin Nanofibers for Ophthalmic DeliveryIn vitro antifungal activity of isavuconazole against Madurella mycetomatisIsavuconazole: A New Option for the Management of Invasive Fungal Infections.Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelKeratitis caused by Aspergillus pseudotamariiPharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Systemic Antifungal Agents: Current Status and Projected Future Developments.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus.Comparative Evaluation of Disc Diffusion and E-test with Broth Micro-dilution in Susceptibility testing of Amphotericin B, Voriconazole and Caspofungin against Clinical Aspergillus isolates.Investigation of multiple resistance mechanisms in voriconazole resistant Aspergillus flavus clinical isolates from a chest hospital surveillance in Delhi, India.In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
P2860
Q28067726-3AD3BB69-F15A-4FFE-8361-ECDFD7CFFBD0Q28068091-8ECF63DA-9D9E-4618-838B-E243E6324784Q28555033-6A6979F7-1008-4D55-BDC3-30F8F2896B32Q34298778-51CB0161-8BFF-47F7-BFB4-F94DC1B13CFCQ34474946-3E49F11F-8E59-45C1-BA81-79824BC8EB31Q34621506-76C6CDD8-DBFC-4EC1-BAAD-EA2EA5F2F8BBQ35385554-F5C6482D-8E4A-4515-9CE7-3562564A70E3Q37454126-6316F836-ABEF-4E5C-9C6F-0E7D5D7EC3ECQ37538782-C7773104-6113-4BAD-BF94-2581DF3AE06BQ38159688-F86F3575-A568-4AD6-9364-FE8BFD41DDB3Q38285488-9BBA9B89-23B1-4B15-9A79-2FB9D12F22E3Q38534865-B4D95D16-B1A7-4862-ABF6-768CE4FBBD3EQ38711698-1E16B7E9-018A-4966-9A11-FE031B0BFEB1Q38796140-1AF88B46-1820-4CC0-8DED-EC4C2B433F40Q38829932-40DDCE9D-808B-4B13-A3DF-F332B5ACA28DQ38914243-C0052793-532A-4147-A98C-E72A30BA0F50Q38939506-FD2462A6-0364-4D11-A631-0775D56B3D06Q39364669-B62A74CB-F663-4503-9F63-63BB8879207BQ39504883-C6F39950-A521-402B-B2E8-BF722C94077FQ40653596-637445F9-4533-44A5-8363-2B8B2B90336CQ42191165-E89D257A-6B09-43EA-A522-40A12C45A4C3Q47193266-467C5C3C-2ECD-4AAD-B887-24A623B22436Q50950336-B0831045-4627-4F4A-A2B3-EB32F1688A9A
P2860
In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
In vitro susceptibility of 188 ...... seven other antifungal drugs.
@en
In vitro susceptibility of 188 ...... seven other antifungal drugs.
@nl
type
label
In vitro susceptibility of 188 ...... seven other antifungal drugs.
@en
In vitro susceptibility of 188 ...... seven other antifungal drugs.
@nl
prefLabel
In vitro susceptibility of 188 ...... seven other antifungal drugs.
@en
In vitro susceptibility of 188 ...... seven other antifungal drugs.
@nl
P2093
P2860
P1433
P1476
In vitro susceptibility of 188 ...... d seven other antifungal drugs
@en
P2093
Arunaloke Chakrabarti
Erik Geertsen
Johan W Mouton
M R Shivaprakash
P2860
P304
P356
10.1111/J.1439-0507.2010.01996.X
P577
2011-04-25T00:00:00Z